GLP-1 Drugs Like Ozempic Linked to 30% Lower Breast Cancer Risk in Major Study
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
Summary
A large observational study from the University of Pennsylvania found that women taking GLP-1 medications — including Ozempic, Wegovy, Mounjaro, and Zepbound — were about 30% less likely to develop breast cancer. The study reviewed health records from over 111,000 women aged 45–80 with a BMI of 25 or higher who underwent breast imaging between 2022 and 2025. Roughly 14% were GLP-1 users. While the findings are promising, researchers caution this is observational data and cannot prove cause and effect. Clinical trials are now being planned to test whether these drugs can actively prevent breast cancer, particularly in high-risk women.
Detailed Summary
GLP-1 receptor agonists — the drug class behind blockbuster medications like Ozempic, Wegovy, Mounjaro, and Zepbound — may offer a powerful benefit beyond weight loss and diabetes management: a substantially lower risk of breast cancer. This finding, presented at the 2026 ASCO Annual Meeting and published in JCO Oncology Practice, adds a compelling new dimension to the already-expanding profile of these widely used drugs.
Researchers at the University of Pennsylvania analyzed electronic health records from 111,646 women aged 45 to 80 with a BMI of 25 or higher who underwent breast imaging within the Penn Medicine health system from January 2022 to June 2025. Of those women, 15,264 had documented GLP-1 prescriptions. The GLP-1 users showed approximately 30% lower rates of breast cancer compared to non-users — a clinically meaningful difference given how common breast cancer is.
GLP-1 drugs work by mimicking a natural gut hormone that regulates appetite and blood sugar. Originally designed for type 2 diabetes, they've grown into dominant weight-loss therapies. Researchers believe their anti-cancer potential may stem from their broad effects on metabolic pathways, inflammation, insulin signaling, and other biological mechanisms associated with tumor development — though the exact mechanisms remain under investigation.
The practical implications are significant. For health-conscious women — especially those who are overweight or at elevated breast cancer risk — GLP-1 medications may provide compounding benefits beyond metabolic health. This positions them as potentially important tools in cancer prevention strategies, not just weight management.
However, critical caveats apply. This is observational research, meaning it cannot confirm that GLP-1 drugs directly caused the risk reduction. Confounding factors such as lifestyle, diet, and overall health-seeking behavior could influence results. Randomized clinical trials, now being planned, are essential before these drugs can be recommended specifically for cancer prevention.
Key Findings
- Women on GLP-1 drugs had ~30% lower breast cancer risk across a 111,000+ patient observational study
- Study included women aged 45–80 with BMI ≥25 undergoing breast imaging at Penn Medicine 2022–2025
- GLP-1 medications affect multiple cancer-related biological pathways beyond weight and blood sugar control
- Findings are observational; randomized clinical trials are now being planned to confirm the association
- High-risk women, including those with prior breast cancer, are being targeted for upcoming GLP-1 trials
Methodology
This is a news report summarizing a peer-reviewed study published in JCO Oncology Practice and presented at the 2026 ASCO Annual Meeting. The source is the University of Pennsylvania Perelman School of Medicine, a highly credible academic institution. Evidence is based on a large retrospective observational study of over 111,000 women, which limits causal inference.
Study Limitations
As an observational study, causality cannot be established and confounding variables may explain part of the risk difference. The study population was limited to Penn Medicine patients, which may not represent broader demographics. Clinical trials are still needed and results are years away; current findings should not drive standalone cancer-prevention prescribing decisions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.